INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Summary

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.

Timeline

Start

2021-03-19

Primary completion

2025-04-01

Completion

2027-11-26

Publications

• Gangat N, Tefferi A. Targeting anemia in myeloid neoplasms. Am J Hematol. 2024 Sep;99(9):1663-1666. doi: 10.1002/ajh.27408. Epub 2024 Jun 5.

Drugs

Indications